RxDoctor Payments Data

Sayed Monis, MD

Neurology · Brawley, CANPI 1942480231

Payments from drug & device makers

$8,222in general payments, 2019–2025

Across 295 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Nevro Corp.$1K
  • Globus Medical$918
  • MDD US Operations, LLC$393
  • AbbVie$318
  • Teva Pharmaceuticals USA, Inc.$186
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$8,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,222 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$3,040,318
Medicare patients
2,238
Services billed
25,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NamzaricMemantine Hcl/Donepezil Hcl40$27,926
Memantine Hcl76$1,014
Carbidopa-LevodopaCarbidopa/Levodopa32$745
Pregabalin25$547
Levetiracetam20$375
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$355
Donepezil Hcl41$276
AmantadineAmantadine Hcl15$256
Cephalexin78$243
Atorvastatin Calcium46$201
Quetiapine Fumarate19$173
ClopidogrelClopidogrel Bisulfate33$149
Duloxetine Hcl11$144
Gabapentin16$127
Diclofenac Sodium11$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric$318$27,92640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Brawley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →